marinedrugs-logo

Journal Browser

Journal Browser

Marine Natural Products as Anticancer Agents, 5th Edition

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 15 February 2026 | Viewed by 111

Special Issue Editors


E-Mail Website
Guest Editor
MARE—Marine and Environmental Sciences Centre, Polytechnic University of Leiria, 2520-630 Peniche, Portugal
Interests: marine natural products; biotechnological applications; pharmaceutical applications; signal transduction; anticancer activities; compounds isolation; anti-inflammatory activity; neuroprotective activity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, College of Pharmacy, Seoul National University, Building 29 Room 223, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
Interests: oncology; signal transduction; cell death; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Based on the success of the Special Issue “Marine Natural Products as Anticancer Agents, 4th Edition” (https://www.mdpi.com/journal/marinedrugs/special_issues/RG72A5PNE8), as well as the critical relevance of this topic, we are pleased to announce the fifth edition of this Special Issue.

This Special Issue will focus on marine organisms that produce compounds with unique chemical structures, which can be used for cancer drug discovery. The manuscripts accepted for this Special Issue will provide in-depth mechanistic insights into the molecular and cellular biology of cancer cells.

Indeed, marine compounds have mechanisms of action that are potentially different from those of drugs derived from terrestrial sources, making them highly valuable in overcoming drug resistance and targeting both solid tumors and hematological malignancies with greater precision. Topics of interest in the development of anticancer therapeutics include recent developments in biotechnology that have created new opportunities for sustainable sourcing of marine-derived compounds, enabling scalable production for use in drug development. Altogether, the exploration and sustainable utilization of marine resources continue to be a promising area in the quest for new therapies to fight cancer.

We therefore invite academic and industry scientists to submit reviews and original and/or conceptual research articles regarding the anticancer activities of known, novel, or derived natural marine compounds, emphasizing the diversity of molecular targets and mechanistic effects. We look forward to the fifth edition of this Special Issue addressing marine compounds and cancer.

Dr. Celso Alves
Prof. Dr. Marc Diederich
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer
  • anti-tumor
  • immune
  • molecular targets
  • co-cultures
  • 3D culture models
  • marine natural products
  • receptors
  • proteins
  • molecular modeling
  • chemical synthesis
  • immune-modulatory

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 3161 KB  
Article
The Marine Natural Compound Aplysinamisine I Selectively Induces Apoptosis and Exhibits Synergy with Taxol™ in Triple-Negative Breast Cancer Spheroids
by Esther A. Guzmán, Tara A. Peterson, Dedra K. Harmody and Amy E. Wright
Mar. Drugs 2025, 23(10), 380; https://doi.org/10.3390/md23100380 - 26 Sep 2025
Abstract
Triple-negative breast cancers (TNBC) lack estrogen, progesterone, and express little, if any, HER2 receptors on their surface. No targeted therapies exist for this aggressive form of breast cancer. A library of enriched fractions from marine organisms was screened in a multi-parametric cytotoxicity assay [...] Read more.
Triple-negative breast cancers (TNBC) lack estrogen, progesterone, and express little, if any, HER2 receptors on their surface. No targeted therapies exist for this aggressive form of breast cancer. A library of enriched fractions from marine organisms was screened in a multi-parametric cytotoxicity assay using MDA-MB-231 and MDA-MB-468 TNBC cells, grown as spheroids (3D cultures). Spheroids better resemble tumors and are considered more clinically predictive. The assay measures apoptosis via the cleavage of caspase 3/7, viability via DNA content, and loss of membrane integrity via 7AAD staining at 24 h of treatment. Fractions were also tested in a traditional 2D MTT assay at 72 h. A fraction from the sponge Aplysina was active in the 3D assay. Aplysinamisine I was identified as the compound responsible for the activity. Aplysinamisine I induces apoptosis in MDA-MB-268 spheroids with an IC50 of 2.9 ± 0.28 µM at 24 h. This novel activity is the most potent for the compound to date. Its IC50 in the MTT assay at 72 h is >80 µM. Striking synergy with Taxol™ is shown in both cell lines. Proteomic analysis led to a differential protein expression profile. Through bioinformatics, this profile led to the hypothesis that the inhibition of nucleophosmin is the potential mode of action of the compound. However, initial studies show only a modest decrease in nucleophosmin expression in spheroids treated with aplysinamisine I. Full article
(This article belongs to the Special Issue Marine Natural Products as Anticancer Agents, 5th Edition)
Show Figures

Figure 1

Back to TopTop